Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anita Katharina Wagner, D.P.H., Dr.Pharm.

Co-Author

This page shows the publications co-authored by Anita Wagner and Dennis Ross-Degnan.
Connection Strength

5.872
  1. Quality use of medicines within universal health coverage: challenges and opportunities. BMC Health Serv Res. 2014 Aug 27; 14:357.
    View in: PubMed
    Score: 0.605
  2. Need for and access to health care and medicines: are there gender inequities? PLoS One. 2013; 8(3):e57228.
    View in: PubMed
    Score: 0.546
  3. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. Health Policy. 2011 May; 100(2-3):151-8.
    View in: PubMed
    Score: 0.460
  4. Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines. BMC Health Serv Res. 2008 Jul 29; 8:161.
    View in: PubMed
    Score: 0.397
  5. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch Intern Med. 2004 Jul 26; 164(14):1567-72.
    View in: PubMed
    Score: 0.301
  6. Effects of state surveillance on new post-hospitalization benzodiazepine use. Int J Qual Health Care. 2003 Oct; 15(5):423-31.
    View in: PubMed
    Score: 0.284
  7. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002 Aug; 27(4):299-309.
    View in: PubMed
    Score: 0.262
  8. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med. 2021 Oct 18.
    View in: PubMed
    Score: 0.248
  9. Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States. JCO Oncol Pract. 2021 02; 17(2):e194-e203.
    View in: PubMed
    Score: 0.233
  10. Quality Reporting by Payers: A Mixed-Methods Study of Provider Perspectives and Practices. Qual Manag Health Care. 2018 Jul/Sep; 27(3):157-164.
    View in: PubMed
    Score: 0.197
  11. Breast Cancer Diagnosis and Treatment After High-Deductible Insurance Enrollment. J Clin Oncol. 2018 04 10; 36(11):1121-1127.
    View in: PubMed
    Score: 0.193
  12. Policies and programs to facilitate access to targeted cancer therapies in Thailand. PLoS One. 2015; 10(3):e0119945.
    View in: PubMed
    Score: 0.157
  13. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract. 2015; 8(1):6.
    View in: PubMed
    Score: 0.156
  14. Uptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand. J Pharm Policy Pract. 2015; 8(1):7.
    View in: PubMed
    Score: 0.156
  15. Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries. Health Policy Plan. 2015 Oct; 30(8):1044-52.
    View in: PubMed
    Score: 0.152
  16. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health Policy. 2014 Jun; 116(2-3):196-205.
    View in: PubMed
    Score: 0.143
  17. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Lancet Glob Health. 2013 Oct; 1(4):e227-37.
    View in: PubMed
    Score: 0.142
  18. Health care payments in the Asia Pacific: validation of five survey measures of economic burden. Int J Equity Health. 2013 Jul 03; 12:49.
    View in: PubMed
    Score: 0.140
  19. Impact of universal health insurance coverage in Thailand on sales and market share of medicines for non-communicable diseases: an interrupted time series study. BMJ Open. 2012; 2(6).
    View in: PubMed
    Score: 0.134
  20. Simulation-based power calculation for designing interrupted time series analyses of health policy interventions. J Clin Epidemiol. 2011 Nov; 64(11):1252-61.
    View in: PubMed
    Score: 0.124
  21. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011 Nov; 130(2):681-9.
    View in: PubMed
    Score: 0.123
  22. Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Serv Res. 2010 Feb 19; 10:42.
    View in: PubMed
    Score: 0.111
  23. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2009 Feb; 62(2):143-8.
    View in: PubMed
    Score: 0.101
  24. Medicines coverage and community-based health insurance in low-income countries. Health Res Policy Syst. 2008 Oct 30; 6:11.
    View in: PubMed
    Score: 0.101
  25. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med. 2007 Jan 16; 146(2):96-103.
    View in: PubMed
    Score: 0.089
  26. Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans. Breast Cancer Res Treat. 2018 Sep; 171(2):449-459.
    View in: PubMed
    Score: 0.049
  27. Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):235-242.
    View in: PubMed
    Score: 0.049
  28. Erratum to: Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 11; 160(2):385.
    View in: PubMed
    Score: 0.044
  29. Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer. Breast Cancer Res Treat. 2016 07; 158(2):333-40.
    View in: PubMed
    Score: 0.043
  30. Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis. BMJ Open. 2016 Mar 17; 6(3):e008671.
    View in: PubMed
    Score: 0.042
  31. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid? Clin Ther. 2015 Jul 01; 37(7):1420-1432.e1.
    View in: PubMed
    Score: 0.040
  32. Out-of-pocket burden of health care spending and the adequacy of the Medicare Part D low-income subsidy. Med Care. 2010 Jun; 48(6):503-9.
    View in: PubMed
    Score: 0.028
  33. Patterns, appropriateness, and predictors of antimicrobial prescribing for adults with upper respiratory infections in urban slum communities of Bangkok. Southeast Asian J Trop Med Public Health. 2005 Mar; 36(2):489-97.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.